Literature DB >> 18327551

NUCEL (Cell and Molecular Therapy Center): a multidisciplinary center for translational research in Brazil.

C Colin1, M A Demasi, T L Degaki, J C Bustos-Valenzuela, R C S Figueira, W R Montor, L O Cruz, F H Lojudice, A G Muras, T M Pereira, S M B Winnischofer, A P G Hasegawa, A C Carreira, N V Verbisck, R G Corrêa, H M Garay-Malpartida, T R Mares-Guia, M L Corrêa-Giannella, J M Granjeiro, M C Sogayar.   

Abstract

Social and economical development is closely associated with technological innovation and a well-developed biotechnological industry. In the last few years, Brazil's scientific production has been steadily increasing; however, the number of patents is lagging behind, with technological and translational research requiring governmental incentive and reinforcement. The Cell and Molecular Therapy Center (NUCEL) was created to develop activities in the translational research field, addressing concrete problems found in biomedical and veterinary areas and actively searching for solutions by employing a genetic engineering approach to generate cell lines over-expressing recombinant proteins to be transferred to local biotech companies, aiming at furthering the development of a national competence for local production of biopharmaceuticals of widespread use and of life-saving importance. To this end, mammalian cell engineering technologies were used to generate cell lines over-expressing several different recombinant proteins of biomedical and biotechnological interest, namely, recombinant human Amylin/IAPP for diabetes treatment, human FVIII and FIX clotting factors for hemophilia, human and bovine FSH for fertility and reproduction, and human bone repair proteins (BMPs). Expression of some of these proteins is also being sought with the baculovirus/insect cell system (BEVS) which, in many cases, is able to deliver high-yield production of recombinant proteins with biological activity comparable to that of mammalian systems, but in a much more cost-effective manner. Transfer of some of these recombinant products to local Biotech companies has been pursued by taking advantage of the São Paulo State Foundation (FAPESP) and Federal Government (FINEP, CNPq) incentives for joint Research Development and Innovation partnership projects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327551     DOI: 10.1007/s12033-008-9052-9

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  34 in total

1.  Optimized insect cell culture for the production of recombinant heterologous proteins and baculovirus particles.

Authors:  C A Pereira; Y Pouliquen; V Rodas; D Massotte; C Mortensen; M C Sogayar; J Ménissier-de Murcia
Journal:  Biotechniques       Date:  2001-12       Impact factor: 1.993

2.  Early detection of productive baculovirus DNA transfection.

Authors:  A V Folgueras-Flatschart; R B Flatschart; M Resende; M C Sogayar
Journal:  Biotechniques       Date:  2000-09       Impact factor: 1.993

3.  The scientific muscle of Brazil's health biotechnology.

Authors:  Marcela Ferrer; Halla Thorsteinsdóttir; Uyen Quach; Peter A Singer; Abdallah S Daar
Journal:  Nat Biotechnol       Date:  2004-12       Impact factor: 54.908

4.  Co-localization of nestin and insulin and expression of islet cell markers in long-term human pancreatic nestin-positive cell cultures.

Authors:  Silvya Stuchi Maria-Engler; Maria Lúcia C Corrêa-Giannella; Letícia Labriola; Karin Krogh; Christian Colin; Fernando Henrique Lojudice; Carlos Alberto Mayora Aita; Elizabeth Maria Costa de Oliveira; Tatiana C Silveira Corrêa; Irenice Cairo da Silva; Tercio Genzini; Marcelo Perosa de Miranda; Irene Lourdes Noronha; Luciano Vilela; Cassio Negro Coimbra; Renato A Mortara; Marcos Mares Guia; Freddy Goldberg Eliaschewitz; Mari Cleide Sogayar
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

5.  Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle.

Authors:  Nadeem Wajih; Susan M Hutson; John Owen; Reidar Wallin
Journal:  J Biol Chem       Date:  2005-07-19       Impact factor: 5.157

6.  Brazil next biotech trailblazer in Latin America?

Authors:  Ricardo Bonalume Neto
Journal:  Nat Biotechnol       Date:  2006-10-05       Impact factor: 54.908

7.  Expression of functional Anopheles merus alpha-amylase in the baculovirus/Spodoptera frugiperda system.

Authors:  P Chimoy Effio; A V Folgueras-Flatschart; W R Montor; F M Pernasetti; M T Pueyo; M C Sogayar; P C Effo
Journal:  Insect Mol Biol       Date:  2003-10       Impact factor: 3.585

8.  Prophylactic use of factor VIII: an economic evaluation.

Authors:  R L Bohn; J Avorn; R J Glynn; I Choodnovskiy; R Haschemeyer; L M Aledort
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

9.  Expression and characterization of mouse cFos protein using the baculovirus expression system: ability to form functional AP-1 complex with coexpressed cJun protein.

Authors:  C M Corvello; R Metz; R Bravo; M C Armelin
Journal:  Cell Mol Biol Res       Date:  1995

10.  PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.

Authors:  L C Wasley; A Rehemtulla; J A Bristol; R J Kaufman
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

View more
  2 in total

1.  In vitro differentiation of cGMP-grade retinal pigmented epithelium from human embryonic stem cells.

Authors:  Fernando H Lojudice; Rodrigo A Brant Fernandes; Francesco Innocenti; Carlos E Franciozi; Priscila Cristovam; Maurício Maia; Mari C Sogayar; Rubens Belfort Junior
Journal:  Int J Retina Vitreous       Date:  2019-10-21

2.  A Fusion between Domains of the Human Bone Morphogenetic Protein-2 and Maize 27 kD γ-Zein Accumulates to High Levels in the Endoplasmic Reticulum without Forming Protein Bodies in Transgenic Tobacco.

Authors:  Valentina Ceresoli; Davide Mainieri; Massimo Del Fabbro; Roberto Weinstein; Emanuela Pedrazzini
Journal:  Front Plant Sci       Date:  2016-03-24       Impact factor: 5.753

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.